142 terminated. 142 Phase 1, 50 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 142 | Terminated 142 |
| Phase 2 | 50 | Terminated 50 |
Follow Autoimmune Diseases: new trials by email Literature Review of Autoimmune Diseases trials Research Report on Autoimmune Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases LUCAR-G79 T cells - Relapsed/Refractory Autoimmune Diseases | Phase 1 | Terminated | Nanjing Legend Biotech Co. | 3 | 2025-07-17 | 2026-06-16 |
| A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus YTS109 cell injection - Lupus Nephritis (LN), Immune Thrombocytopenia (ITP) | Phase 1 | Terminated | China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 | 2025-04-16 | 2026-10-14 |
| Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes Lyumjev 100 UNT/ML Injectable Solution, Premixed Lyumjev - Type 1 Diabetes | Phase 1 / Phase 2 | Terminated | St. Olavs Hospital | 9 | 2025-04-01 | 2026-10-19 |
| Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) Kamuvudine-9 - Thyroid Eye Disease | Phase 1 | Terminated | Peter Timoney | 4 | 2024-11-06 | 2026-04-01 |
| A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome ASP5502, Placebo - Healthy Volunteers, Sjögren's Syndrome | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 116 | 2024-08-21 | 2026-09-14 |
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 3 | 2024-08-06 | 2026-08-31 |
| Safety of Bryostatin in Patients With MS Bryostatin 1 - Multiple Sclerosis | Phase 1 | Terminated | Robert Fox | 4 | 2024-06-26 | 2026-03-31 |
| Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) Filgotinib - Juvenile Idiopathic Arthritis | Phase 1 | Terminated | Alfasigma S.p.A. | 9 | 2024-05-13 | 2026-07-15 |
| CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy ThisCART19A - Autoimmune Hemolytic Anemia, CD19 CAR-T Cell Infusion | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 1 | 2024-01-20 | 2026-11-04 |
| Study of GS-0272 in Participants With Rheumatoid Arthritis GS-0272, Placebo - Rheumatoid Arthritis | Phase 1 | Terminated | Gilead Sciences | 55 | 2023-09-28 | 2026-05-27 |
| A Study of Imvotamab in Severe Systemic Lupus Erythematosus Imvotamab - Systemic Lupus Erythematosus, Lupus Erythematosus | Phase 1 | Terminated | IGM Biosciences, Inc. | 17 | 2023-08-15 | 2025-02-10 |
| Siplizumab in T1DM Siplizumab - Type 1 Diabetes Mellitus | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2023-05-18 | 2026-07-28 |
| KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 6 | 2023-04-28 | 2026-08-31 |
| A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis Imvotamab, Placebo - Rheumatoid Arthritis, Arthritis, Rheumatoid | Phase 1 | Terminated | IGM Biosciences, Inc. | 33 | 2023-03-15 | 2025-02-18 |
| An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D VCTX211 - Diabetes Mellitus, Diabetes Mellitus, Type 1 | Phase 1 | Terminated | CRISPR Therapeutics AG | 5 | 2023-01-20 | 2026-05-07 |
| PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy Linperlisib - Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment | Phase 1 | Terminated | Institute of Hematology & Blood Diseases Hospital, China | 4 | 2023-01-13 | 2026-02-11 |
| KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - WHO Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 2 | 2022-12-01 | 2026-08-31 |
| Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) Dapagliflozin, Placebo oral tablet, Stress - Type 1 Diabetes, Diabetic Ketoacidosis | Phase 1 | Terminated | Kinderkrankenhaus auf der Bult | 2 | 2022-05-18 | 2024-12-09 |
| Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE) MHS552, Placebo - Lupus Erythematosus, Systemic | Phase 1 | Terminated | Novartis Pharmaceuticals | 8 | 2022-03-15 | 2024-10-09 |
| A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus Placebo, TJ202 injection - Systemic Lupus Erythematosus (SLE) | Phase 1 | Terminated | TJ Biopharma Co., Ltd. | 1 | 2021-12-30 | 2024-04-15 |
Showing 20 of 142. Sign in to see all of them.
Multiple Sclerosis (31) · Arthritis, Rheumatoid (29) · Diabetes Mellitus, Type 1 (29) · Lupus Erythematosus, Systemic (18) · Multiple Sclerosis, Relapsing-Remitting (9) · Purpura, Thrombocytopenic, Idiopathic (9) · Arthritis (6) · Lupus Nephritis (5) · Anemia, Hemolytic, Autoimmune (4) · Diabetes Mellitus (4) · Hypoglycemia (4) · Diabetes Mellitus, Type 2 (3) · Inflammation (3) · Multiple Sclerosis, Chronic Progressive (3)
Immune System Diseases (141) · Skin and Connective Tissue Diseases (57) · Connective Tissue Diseases (53) · Nervous System Diseases (40) · Autoimmune Diseases of the Nervous System (39) · Musculoskeletal Diseases (36) · Demyelinating Autoimmune Diseases, CNS (35) · Demyelinating Diseases (35) · Joint Diseases (33) · Rheumatic Diseases (32) · Nutritional and Metabolic Diseases (30) · Endocrine System Diseases (29) · Metabolic Diseases (29) · Glucose Metabolism Disorders (28)
Cyclophosphamide (6) · Rituximab (6) · fludarabine (5) · Alemtuzumab (4) · Hematopoietic Stem Cell Transplantation (4) · Islets of Langerhans Transplantation (3) · Methylprednisolone (3) · Staphylococcal Protein A (3) · thymoglobulin (3) · Abatacept (2) · Etanercept (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Indium-105 (2) · Mesna (2)
GlaxoSmithKline (7) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Northwestern University (4) · Amgen (3) · Kyverna Therapeutics (3) · Protalex, Inc. (3) · Alexion Pharmaceuticals, Inc. (2) · Biocon Limited (2) · Bristol-Myers Squibb (2) · Elan Pharmaceuticals (2) · Gilead Sciences (2) · IGM Biosciences, Inc. (2) · Institute for Neurodegenerative Disorders (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Mayo Clinic (2)
United States (81) · United Kingdom (18) · Canada (12) · Germany (12) · Poland (10) · Spain (8) · Belgium (7) · France (7) · Netherlands (7) · China (6) · Russia (6) · Australia (5) · New Zealand (5) · Hungary (4) · Italy (4)
Richard Burt, MD (6) · Albert Lo, MD PhD (2) · Anna Haemel, MD (2) · Abhimanyu Garg, M.D. (1) · Alasdair Coles, Phd FRCP (1) · Amir Moheet, MD (1) · Andrew D Goodman, MD (1)
PMID 12542793, PMID 15864738, PMID 21412424, PMID 22448235, PMID 22634621, PMID 23829485, PMID 23982748, PMID 23991111, PMID 24759263, PMID 25442786, PMID 26068866, PMID 26590659, PMID 27055915, PMID 27515248, PMID 27574516, PMID 28118537, PMID 28542350, PMID 29317381, PMID 29420708, PMID 31063156, PMID 31072380, PMID 32232095, PMID 32248659, PMID 32359360, PMID 33318163, PMID 34126109, PMID 34193595, PMID 34773923, PMID 37831074, PMID 38104476, PMID 38241758, PMID 40211481, PMID 40308078, PMID 41141513, PMID 41706381, PMID 42023429, PMID 42168649
2014 (3), 2018 (3), 2023 (3), 2017 (2), 2004 (1), 2015 (1), 2019 (1), P01HL075462 (1), R21AR069226 (1), R34AT007837 (1), UL1RR024150 (1)